CYP19A1 and breast carcinoma: In our in silico analysis, we recently showed that, apart from repressing MYC, ras, and HMGA2, let-7 may also target CYP19A1, ESR1, and ESR2, thereby potentially blocking estrogen signalling in er-positive breast cancers.